Want to see LAB full AI Analyst Report?
Top Page
Standard BioTools
(NASDAQ:LAB)
Select Model
Select Model
Rating:43Neutral
Price Target:
$0.62
▼(-24.94% Downside)
Action:Reiterated
Date:08/06/26
LAB scores low primarily due to severe operating losses and continued cash burn, reinforced by bearish technicals with the stock trading below key moving averages. Corporate events provide some offset via merger-driven repositioning and cash-related actions, but listing-risk headlines and the lack of profitability keep the overall score constrained; valuation is difficult to support given the negative P/E and no dividend.
Positive Factors
Resilient Gross Margin
A gross margin near 49% indicates the core instruments, consumables and assay offerings retain meaningful unit economics. This provides a foundation for future operating leverage if management can stabilize demand and reduce expenses.
Negative Factors
Severe Revenue Contraction
The sharp revenue decline indicates material weakness or volatility in customer demand, product mix and instrument placements. Lower scale makes fixed operating costs harder to absorb and reduces the recurring consumables opportunity from the installed base.
Read all positive and negative factors
Positive Factors
Negative Factors
Resilient Gross Margin
A gross margin near 49% indicates the core instruments, consumables and assay offerings retain meaningful unit economics. This provides a foundation for future operating leverage if management can stabilize demand and reduce expenses.
Read all positive factors
Standard BioTools Key Performance Indicators (KPIs)
Any
Revenue by Segment
Shows how sales are split across the company’s business lines (for example instruments, consumables and services, and major geographies). A larger share of consumables and services usually means steadier, higher-margin recurring revenue, while dependence on one-time instrument sales signals more revenue volatility and capital intensity — so the split reveals growth sustainability, margin profile, and exposure to demand cycles.
Shows how sales are split across the company’s business lines (for example instruments, consumables and services, and major geographies). A larger share of consumables and services usually means steadier, higher-margin recurring revenue, while dependence on one-time instrument sales signals more revenue volatility and capital intensity — so the split reveals growth sustainability, margin profile, and exposure to demand cycles.
Data provided by:
The Fly
The FlyStandard BioTools (LAB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$262.64M
Dividend YieldN/A
Average Volume (3M)3.82M
Price to Earnings (P/E)―
Beta (1Y)1.59
Revenue Growth-45.15%
EPS Growth29.58%
CountryUS
Employees387
SectorHealthcare
Sector Strength45
IndustryMedical - Specialties
Share Statistics
EPS (TTM)-0.23
Shares Outstanding392,578,800
10 Day Avg. Volume1,722,820
30 Day Avg. Volume3,820,955
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)1.15
Price to Sales (P/S)5.72
P/FCF Ratio-5.91
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.03
Revenue Forecast (FY)$82.48M
Standard BioTools Business Overview & Revenue Model
Company Description
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle Ea...
How the Company Makes Money
Standard BioTools generates revenue primarily by selling life science research products tied to its instrument platforms. Key revenue streams include: (1) Instrument sales: one-time sales of hardware systems (e.g., mass cytometry and other analyti...
Standard BioTools Earnings Call Summary
Earnings Call Date:May 06, 2025
(Q1-2025)
| % Change Since: |
Next Earnings Date:Nov 10, 2026
Earnings Call Sentiment Neutral
The earnings call reflected a well-managed quarter with robust strategic initiatives and strong cost management, despite facing significant revenue declines and challenges in the U.S. academic market. The company's strong cash position and strategic product expansions provide a positive outlook, though the impact of tariffs and revenue declines remain concerns.Positive Updates
Strategic Product Launches and Expansions
Standard BioTools announced a new SomaScan offering and expanded its reach with the NGS-based Illumina partner solution, enhancing translational and clinical research capabilities.
Negative Updates
Revenue Decline
Total revenue fell by 10% year-over-year, with consumables down by 16% and services down by 16%, due to lower volumes and project timing.
Read all updates
Q1-2025 Updates
Positive
Negative
Strategic Product Launches and Expansions
Standard BioTools announced a new SomaScan offering and expanded its reach with the NGS-based Illumina partner solution, enhancing translational and clinical research capabilities.
Read all positive updates
Company Guidance
During the Standard BioTools first quarter 2025 earnings call, the company reiterated its full-year revenue guidance of $165 million to $175 million, despite a 10% year-over-year decline in Q1 revenue to $40.8 million. The decline was primarily due to lower consumables and services revenue, with consumables down 16% and services down 16% year-over-year. Instrument sales, however, grew by 24%, driven by the Hyperion XTi system. The company reported non-GAAP gross margins of 53.2%, impacted by lower volumes and product mix, and a non-GAAP operating loss improvement of 45% year-over-year. Adjusted EBITDA loss improved 29% to $16.9 million, and cash burn was reduced by 33%. The company emphasized its strategic focus on proteomics and highlighted new product launches, including the CyTOF-XT Pro and SomaScan Select Asset, as key drivers for future growth.Standard BioTools Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 84.60M | 85.33M | 174.43M | 106.34M | 97.95M | 130.58M |
| Gross Profit | 41.57M | 42.54M | 84.26M | 50.45M | 37.05M | 69.37M |
| EBITDA | -91.90M | -89.69M | -118.14M | -54.46M | -173.57M | -44.27M |
| Net Income | -87.38M | -74.90M | -138.88M | -74.66M | -190.10M | -59.24M |
Balance Sheet | ||||||
| Total Assets | 627.22M | 567.75M | 612.34M | 323.07M | 390.31M | 275.21M |
| Cash, Cash Equivalents and Short-Term Investments | 476.72M | 187.57M | 292.87M | 114.89M | 165.78M | 28.45M |
| Total Debt | 28.09M | 30.83M | 33.00M | 98.21M | 102.66M | 111.65M |
| Total Liabilities | 87.25M | 143.46M | 140.62M | 471.12M | 471.78M | 180.62M |
| Stockholders Equity | 539.97M | 424.29M | 471.72M | -148.05M | -81.47M | 94.60M |
Cash Flow | ||||||
| Free Cash Flow | -82.58M | -82.65M | -151.81M | -46.12M | -93.19M | -57.33M |
| Operating Cash Flow | -80.31M | -74.35M | -143.45M | -43.29M | -89.37M | -44.06M |
| Investing Cash Flow | 188.13M | 24.77M | 363.17M | 20.24M | -88.13M | -11.95M |
| Financing Cash Flow | 330.00K | 570.00K | -102.62M | -6.81M | 230.76M | 15.96M |
Standard BioTools Technical Analysis
Negative
0.83
Price Trends
0.82
Negative
0.90
Negative
1.09
Negative
Market Momentum
-0.05
Positive
35.05
Neutral
13.17
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LAB, the sentiment is Negative. The current price of 0.83 is above the 20-day moving average (MA) of 0.77, above the 50-day MA of 0.82, and below the 200-day MA of 1.09, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 35.05 is Neutral, neither overbought nor oversold. The STOCH value of 13.17 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LAB.
Standard BioTools Risk Analysis
Standard BioTools disclosed 50 risk factors in its most recent earnings report. Standard BioTools reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Standard BioTools Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | $2.51B | 22.59 | 32.81% | ― | 34.41% | 90.73% | |
71 Outperform | $1.04B | -51.86 | -4.15% | ― | 3.18% | -100.37% | |
54 Neutral | $1.96B | -16.86 | -46.47% | ― | -13.26% | 14.26% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $547.55M | -7.06 | -7.87% | ― | 6.83% | -69.59% | |
47 Neutral | $306.08M | -2.68 | -32.59% | ― | -3.16% | 72.02% | |
43 Neutral | $262.64M | -2.90 | -18.16% | ― | -45.15% | 29.58% |
* Healthcare Sector Average
LAB
Standard BioTools
0.67
-0.57
-46.05%
MYGN
Myriad Genetics
3.20
-2.69
-45.67%
CDNA
CareDx
48.61
35.86
281.25%
FLGT
Fulgent Genetics
19.90
-1.63
-7.57%
PSNL
Personalis
18.38
13.68
291.06%
CSTL
Castle Biosciences
34.20
13.63
66.26%
Standard BioTools Corporate Events
Business Operations and StrategyFinancial DisclosuresM&A Transactions
Standard BioTools Q2 Results Highlight Strategic Restructuring
Neutral
Aug 5, 2026
Standard BioTools reported second-quarter 2026 revenue of $20.1 million, down 7.6% year-over-year, with declines across consumables, instruments and services, but improved gross margins driven by productivity gains and lower warranty costs. Despit...
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
Standard BioTools Divests Mass Cytometry to Multiplex Bio
Positive
Jul 28, 2026
On July 24, 2026, Standard BioTools agreed a termination and waiver deal with Illumina under which it received about $30 million in cash in exchange for relinquishing a 2026 earnout and future royalty rights tied to Illumina’s earlier acquis...
Delistings and Listing ChangesRegulatory Filings and ComplianceStock Split
Standard BioTools Receives Nasdaq Bid Price Deficiency Notice
Negative
Jul 24, 2026
On July 22, 2026, Standard BioTools disclosed that it had received a notice from Nasdaq stating the company no longer meets the exchange’s minimum $1.00 bid price requirement, after its shares closed below that level for 30 consecutive busin...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Standard BioTools Shareholders Approve 2026 Equity Incentive Plans
Positive
Jun 18, 2026
Standard BioTools Inc. held its 2026 Annual Meeting of Stockholders on June 17, 2026, where shareholders approved the company’s 2026 Equity Incentive Plan and an amendment to the Amended and Restated 2017 Employee Stock Purchase Plan, adding...
Business Operations and StrategyM&A TransactionsStock Split
Standard BioTools to Merge with Treeline Biosciences
Positive
Jun 8, 2026
On June 6, 2026, Standard BioTools agreed to merge with Treeline Biosciences in an all-stock transaction valuing Treeline at about $2.5 billion and Standard BioTools at roughly $460 million, creating a company in which Treeline shareholders will o...
Delistings and Listing ChangesRegulatory Filings and Compliance
Standard BioTools Regains Nasdaq Minimum Bid Compliance Status
Positive
Jun 5, 2026
On June 5, 2026, Standard BioTools Inc. announced it had received a letter from Nasdaq’s Listing Qualifications Department confirming the company had regained compliance with the exchange’s minimum bid price requirement. The notificati...
Executive/Board Changes
Standard BioTools Grants RSUs to Chief Business Officer
Neutral
Jun 3, 2026
On May 29, 2026, Standard BioTools’ Human Capital Committee approved a grant of 500,000 restricted stock units to Chief Business Officer Sean Mackay under the company’s 2026 Equity Incentive Plan, with the award becoming effective on J...
Business Operations and StrategyExecutive/Board Changes
Standard BioTools Adopts New Executive Severance Protection Plans
Positive
May 28, 2026
On May 21, 2026, Standard BioTools’ board approved a 2026 Change of Control and Severance Plan for its executive leadership team, excluding the CEO, with a term through August 4, 2028 and enhanced protections for qualifying terminations. The...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.